NIDA’s Clinical Trials Network (CTN) is an enterprise in which NIDA, treatment researchers, and community-based service providers work toward new treatment options in community-level clinical practice.

Studies

Study 29 – Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048

Study 31 – Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT); CTN-0051

Study 32 – Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053

Study 37 – Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder; CTN-0068

Study 39 – Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT)

Study 40 – Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY); CTN-0098

Study 41 – Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; CTN-0100

Study 44 – Randomized, Placebo-Controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2); CTN-0109

Study 45 – Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB); CTN-0110

Study 47 – Ketamine for Methamphetamine Use Disorder (KMD); CTN-0132